Share This Link

Administering insulin twice daily (morning and afternoon) is typical for intermediate-acting insulins (e.g., NPH), not for insulin glargine. Glargine is designed for once-daily dosing due to its long, steady action.

Giving insulin 15–30 minutes before meals is appropriate for short-acting insulin (e.g., regular insulin), which is intended to control postprandial glucose spikes. Insulin glargine is not meal-related and should not be timed with meals.

Administering insulin after meals and at bedtime is more consistent with rapid-acting insulin regimens or correctional insulin. Insulin glargine is basal insulin, not used for immediate glucose control after eating.

Epinephrine is a vasoconstrictor, meaning it narrows blood vessels at the injection site. This leads to decreased blood flow rather than increased perfusion. Although this helps reduce bleeding, the statement is incorrect because it describes the opposite effect.

Epinephrine decreases, not increases, the rate of absorption of lidocaine. Slower absorption is essential for maintaining the drug’s local effect and preventing it from rapidly entering systemic circulation.

Increasing systemic absorption would raise blood levels of lidocaine and increase the risk of toxicity. The purpose of adding epinephrine is to limit systemic exposure, not enhance it.

Aspiration is not required when administering insulin because it is given into the subcutaneous tissue, which does not contain large blood vessels that would necessitate checking for blood return. Current practice guidelines recommend not aspirating, as it can cause unnecessary tissue trauma and discomfort without improving safety.

Regular insulin (short-acting) and NPH insulin (intermediate-acting) are compatible and can be mixed in the same syringe, allowing administration in a single injection. This reduces the number of injections the client must take. When mixing, the nurse should draw up regular insulin first (clear) and then NPH insulin (cloudy) to avoid contaminating the regular insulin vial.

Insulin must be administered into the subcutaneous layer, typically in areas such as the abdomen, thigh, or upper arm. Injecting into a large muscle (intramuscular route) would result in faster and unpredictable absorption, significantly increasing the risk of hypoglycemia. Proper technique includes rotating injection sites to prevent lipodystrophy.

Propranolol does not significantly increase insulin requirements through receptor blocking. While beta-blockers affect adrenergic receptors, they do not directly cause a predictable increase in insulin dosage needs.

Beta-blockers are not primarily associated with causing insulin resistance. Their main concern in diabetic patients is related to hypoglycemia awareness rather than altering insulin sensitivity.

The combination of insulin and propranolol does not directly increase the risk of diabetic ketoacidosis. Ketoacidosis is typically related to insufficient insulin, infection, or stress, not beta-blocker use.

While adherence is important, questioning the patient about taking medication may feel accusatory and is not the most appropriate initial response. Many patients do take their medication correctly but still do not feel better immediately due to the drug’s pharmacokinetics.

Diet can affect absorption (e.g., calcium or iron supplements), but this is not typically the primary reason a patient would not feel better after only 1 week of therapy. Focusing on diet at this early stage is premature.

Surgery is not required for typical hypothyroidism. The standard treatment is lifelong thyroid hormone replacement, and surgery is only indicated in specific conditions, such as large goiters or thyroid cancer.

Metformin does not stimulate the pancreas to produce insulin. Drugs that increase insulin secretion, such as sulfonylureas, work by directly prompting beta cells to release more insulin. Since metformin acts differently, this description is inaccurate.

This description applies to GLP-1 receptor agonists (e.g., exenatide, liraglutide). These drugs increase insulin secretion, suppress glucagon release, and slow gastric emptying to reduce postprandial glucose spikes. Metformin does not have these effects.

Slowing carbohydrate absorption is the mechanism of alpha-glucosidase inhibitors (e.g., acarbose, miglitol), which delay the breakdown and absorption of starches in the small intestine. Metformin does not act in this way.

Methimazole can occasionally cause mild liver enzyme elevations, but severe hepatotoxicity is rare. Significant liver toxicity is more commonly associated with propylthiouracil (PTU) than methimazole. Therefore, while liver function should be monitored, it is not the most dangerous toxicity of methimazole.

Thyrotoxicosis is a state of excess thyroid hormone, often resulting from hyperthyroidism or over-replacement of thyroid hormone therapy. Methimazole is used to treat hyperthyroidism, so it does not induce thyrotoxicosis; this makes it an irrelevant option for methimazole toxicity.

PTU toxicity refers specifically to the adverse effects associated with propylthiouracil, including liver failure and vasculitis. While related pharmacologically, this is not directly a toxicity of methimazole, which has a different adverse effect profile.

While inhalation anesthetics can produce muscle relaxation and unconsciousness, balanced anesthesia is not limited to a single inhalation agent; it refers to a combination of drugs used to achieve multiple anesthetic goals.

Brief induction and rapid emergence describe ultra-short-acting anesthetics, not the concept of balanced anesthesia. Balanced anesthesia focuses on using multiple agents for complementary effects, rather than speed of onset or recovery.

While minimizing respiratory side effects is desirable, balanced anesthesia is not defined by a single goal like analgesia or respiratory safety. It is defined by the strategic use of multiple drugs to produce all necessary components of anesthesia safely and effectively.